A carregar...
Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA
BACKGROUND: Compared with basal-bolus insulin therapy (insulin glargine U100 plus insulin aspart), IDegLira has been shown to be associated with similar improvements in HbA1c, with superior weight loss and reduced hypoglycemia in patients with type 2 diabetes. The present analysis evaluated the cost...
Na minha lista:
| Publicado no: | Clinicoecon Outcomes Res |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6432901/ https://ncbi.nlm.nih.gov/pubmed/30962697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S194719 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|